-
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) JAMA (IF 63.1) Pub Date : 2024-11-18 Steven E. Nissen, Qiuqing Wang, Stephen J. Nicholls, Ann Marie Navar, Kausik K. Ray, Gregory G. Schwartz, Michael Szarek, Erik S. G. Stroes, Roland Troquay, Jannick A. N. Dorresteijn, Henry Fok, David A. Rider, Steven Romano, Kathy Wolski, Curtis Rambaran
ImportanceElevated lipoprotein(a) increases the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis.ObjectiveTo evaluate the effects of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), on lipoprotein(a) serum concentration.Design, Setting, and ParticipantsA multicenter trial in patients with stable ASCVD with serum lipoprotein(a) concentrations
-
Oral Muvalaplin for Lowering of Lipoprotein(a) JAMA (IF 63.1) Pub Date : 2024-11-18 Stephen J. Nicholls, Wei Ni, Grace M. Rhodes, Steven E. Nissen, Ann Marie Navar, Laura F. Michael, Axel Haupt, John H. Krege
ImportanceMuvalaplin inhibits lipoprotein(a) formation. A 14-day phase 1 study demonstrated that muvalaplin was well tolerated and reduced lipoprotein(a) levels up to 65%. The effect of longer administration of muvalaplin on lipoprotein(a) levels in individuals at high cardiovascular risk remains uncertain.ObjectivesTo determine the effect of muvalaplin on lipoprotein(a) levels and to assess safety
-
Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease-Reply. JAMA (IF 63.1) Pub Date : 2024-11-18 Brian Lipworth,Mintu Nath,Graham Devereux
-
Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial. JAMA (IF 63.1) Pub Date : 2024-11-18 Caihua Sang,Qiang Liu,Yiwei Lai,Shijun Xia,Ruhong Jiang,Songnan Li,Qi Guo,Qifan Li,Mingyang Gao,Xueyuan Guo,Lihong Huang,Nian Liu,Chenxi Jiang,Song Zuo,Xiaoxia Liu,Mengmeng Li,Weili Ge,Shangming Song,Lianghua Chen,Shuanglun Xie,Jiangang Zou,Ke Chen,Xiangfei Liu,Hesheng Hu,Xinhua Wang,Jinlin Zhang,Zhaojun Wang,Chi Wang,Liu He,Chao Jiang,Ribo Tang,Ning Zhou,Yunlong Wang,Deyong Long,Xin Du,Chenyang Jiang
Importance Success rates of pulmonary vein isolation (PVI) are modest for persistent atrial fibrillation (AF). Additional linear ablation beyond PVI has not been proved superior to PVI alone in randomized trials. Ethanol infusion of the vein of Marshall (EIVOM) facilitates ablation at the mitral isthmus and may lead to improved effectiveness of a linear ablation strategy. Objective To determine whether
-
Beyond Pulmonary Vein Isolation-Bringing Persistent Atrial Fibrillation in Line With Alcohol. JAMA (IF 63.1) Pub Date : 2024-11-18 Miguel Valderrábano
-
Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease. JAMA (IF 63.1) Pub Date : 2024-11-18 Chi-Kuei Hsu,Chih-Cheng Lai
-
Harm Reduction Strategies for People Who Use Drugs JAMA (IF 63.1) Pub Date : 2024-11-18 Ruchi V. Shah, Joseph Shay, Miriam Komaromy
This JAMA Insights explores harm reduction strategies for people who use drugs and the clinicians who treat them to help reduce the risk of unintentional drug overdose and infection.
-
Caregiver-Reported Quality in Hospices Owned by Private Equity Firms and Publicly Traded Companies JAMA (IF 63.1) Pub Date : 2024-11-18 Alexander E. Soltoff, Mark Aaron Unruh, David G. Stevenson, Dio Kavalieratos, Robert Tyler Braun
This study compares differences in caregiver-reported hospice quality across categories of ownership, including for-profit private equity firm (PEF)/publicly traded company (PTC)–owned and non-PEF/PTC–owned hospices as well as not-for-profit–owned hospices.
-
The US Preventive Services Task Force and Precision Prevention JAMA (IF 63.1) Pub Date : 2024-11-18 Michael J. Barry, Michael Silverstein, Wanda Nicholson
This Viewpoint summarizes how the US Preventive Services Task Force specifies target populations for its recommendations and highlights 3 problems—including exacerbation of health inequities—posed by the proposed use of more complex risk models to better identify target populations and increase effectiveness and efficiency of prevention efforts (“precision prevention”).
-
Diagnosis and Treatment of Polycythemia Vera JAMA (IF 63.1) Pub Date : 2024-11-18 Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas, Ronald Hoffman
ImportancePolycythemia vera (PV), a myeloproliferative neoplasm characterized by an increased red blood cell mass and increased risk of thrombosis, affects approximately 65 000 people in the US, with an annual incidence of 0.5 to 4.0 cases per 100 000 persons.ObservationsErythrocytosis (hemoglobin >16.5 mg/dL in men or >16.0 mg/dL in women) is a required diagnostic criterion, although thrombocytosis
-
Communication About Harm Reduction With Patients Who Have Opioid Use Disorder JAMA (IF 63.1) Pub Date : 2024-11-18 Mary Hawk, Raagini Jawa, Emma Sophia Kay
This JAMA Insights explores how clinicians can use the harm reduction communication framework to engage with patients who have opioid use disorder, which could help prevent overdose and other substance use–related harms.
-
Polygenic Risk Scores for Coronary Heart Disease: An Unfulfilled Promise of Precision Medicine. JAMA (IF 63.1) Pub Date : 2024-11-16 Sadiya S Khan,Michael J Pencina
-
Evaluating Performance and Agreement of Coronary Heart Disease Polygenic Risk Scores. JAMA (IF 63.1) Pub Date : 2024-11-16 Sarah A Abramowitz,Kristin Boulier,Karl Keat,Katie M Cardone,Manu Shivakumar,John DePaolo,Renae Judy,Francisca Bermudez,Nour Mimouni,Christopher Neylan,Dokyoon Kim,Daniel J Rader,Marylyn D Ritchie,Benjamin F Voight,Bogdan Pasaniuc,Michael G Levin,Scott M Damrauer,
Importance Polygenic risk scores (PRSs) for coronary heart disease (CHD) are a growing clinical and commercial reality. Whether existing scores provide similar individual-level assessments of disease susceptibility remains incompletely characterized. Objective To characterize the individual-level agreement of CHD PRSs that perform similarly at the population level. Design, Setting, and Participants
-
Lower Suicide Risks in Adolescents With Obesity Taking GLP-1 Drugs. JAMA (IF 63.1) Pub Date : 2024-11-15 Samantha Anderer
-
Study Offers Insights Into Male HPV Infection's Potential Role in Infertility. JAMA (IF 63.1) Pub Date : 2024-11-15 Lori Youmshajekian
-
Mental Health First Aid Advances Into the Workplace, but Questions Remain. JAMA (IF 63.1) Pub Date : 2024-11-15 Anna Bock
-
Bystander Use of Opioid Overdose Antidote Naloxone Is on the Rise. JAMA (IF 63.1) Pub Date : 2024-11-15 Samantha Anderer
-
Study: BMI May Underestimate Obesity-Linked Breast Cancer Risk. JAMA (IF 63.1) Pub Date : 2024-11-15 Samantha Anderer
-
FDA Approves New Class of Hemophilia Treatment. JAMA (IF 63.1) Pub Date : 2024-11-15 Samantha Anderer
-
Trial Supports Acupuncture for Chronic Sciatica Pain. JAMA (IF 63.1) Pub Date : 2024-11-15 Samantha Anderer
-
Early COVID-19 Infections Linked With Higher Heart Attack, Stroke Risk. JAMA (IF 63.1) Pub Date : 2024-11-15 Samantha Anderer
-
Study: Prenatal Cannabis Use Not Associated With Developmental Delays. JAMA (IF 63.1) Pub Date : 2024-11-15 Samantha Anderer
-
ACOG Now Recommends Breast Cancer Screenings Start at Age 40. JAMA (IF 63.1) Pub Date : 2024-11-15 Samantha Anderer
-
AI Can’t Worry About Patients, and a Clinical Ethicist Says That Matters JAMA (IF 63.1) Pub Date : 2024-11-15 Yulin Hswen, Jennifer Abbasi
This Medical News article is an interview with Sarah C. Hull, MD, MBE, a cardiologist and clinical ethicist at Yale School of Medicine, about appropriate boundaries for use of artificial intelligence in clinical settings.
-
Election Night JAMA (IF 63.1) Pub Date : 2024-11-15 Andrew F. Beck
While watching the 2024 election night results and considering possible health care policies, a pediatrician reflects on his role in engaging in conversations about politics and policy as an advocate for patients.
-
Why Evidence Generation Should Matter to Payers. JAMA (IF 63.1) Pub Date : 2024-11-14 Joshua Hauser,Rita F Redberg
-
Why Evidence Generation Should Matter to Payers-Reply. JAMA (IF 63.1) Pub Date : 2024-11-14 Ali B Abbasi,Lesley H Curtis,Robert M Califf
-
Artemisinin Partial Resistance and the Treatment of Severe Malaria. JAMA (IF 63.1) Pub Date : 2024-11-14 Philip J Rosenthal
-
Strengthening Hurricane Preparedness in Hospital Systems. JAMA (IF 63.1) Pub Date : 2024-11-14 Attila J Hertelendy,Gregory Ciottone
-
The Burden of Choice JAMA (IF 63.1) Pub Date : 2024-11-14 Jessica Chen
In this narrative medicine essay, a family planning fellow discusses how undergoing an abortion, the procedure she specializes in performing, has deepened her perception of the concept of the difficult components of choice and helped her understand the difference in providing vs experiencing care.
-
Trends in Hospitalizations and Liver Transplants Associated With Alcohol-Induced Liver Disease JAMA (IF 63.1) Pub Date : 2024-11-14 Vrishketan Sethi, Ramon Bataller, Hao Liu, Kristine M. Ruppert, Michele Molinari
This study investigates trends in hospitalization and liver transplant rates in the US from 2005 to 2021 associated with alcohol-induced liver disease.
-
The Carceral-Community Cascade and HCV Elimination JAMA (IF 63.1) Pub Date : 2024-11-14 Matthew J. Akiyama, Tessa Bialek, Raphael Simonson
This Viewpoint discusses a sector-wide approach to hepatitis C virus elimination, including not only jails and prisons, but also community supervision and alternatives to incarceration programs.
-
Tenofovir and Hepatitis B Virus Transmission During Pregnancy JAMA (IF 63.1) Pub Date : 2024-11-14 Calvin Q. Pan, Erhei Dai, Zhongfu Mo, Hua Zhang, Thomas Q. Zheng, Yuming Wang, Yingxia Liu, Tianyan Chen, Suwen Li, Cuili Yang, Jinjuan Wu, Xiuli Chen, Huaibin Zou, Shanshan Mei, Lin Zhu
ImportanceStandard care for preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV) in highly viremic mothers consists of maternal antiviral prophylaxis beginning at gestational week 28 combined with an HBV vaccine series and HBV immune globulin (HBIG) at birth. However, HBIG is unavailable in some resource-limited areas.ObjectiveTo determine whether initiating tenofovir disoproxil
-
Artemisinin Partial Resistance in Ugandan Children With Complicated Malaria JAMA (IF 63.1) Pub Date : 2024-11-14 Ryan C. Henrici, Ruth Namazzi, Giselle Lima-Cooper, Charles Kato, Sadati Aliwuya, Jamille G. Dombrowski, Sade Pratt, Susana Campino, Andrea L. Conroy, Colin J. Sutherland, Chandy C. John, Robert O. Opoka
This study assesses artemisinin partial resistance, Pfkelch13 variations, and malaria recrudescence in Ugandan children with complicated malaria.
-
Symptom Monitoring With Patient-Reported Outcomes During Pediatric Cancer Care. JAMA (IF 63.1) Pub Date : 2024-11-13 Ethan Basch,Allison Barz Leahy,Bryce B Reeve
-
Selective vs Standard Obstetric Thromboprophylaxis Protocol. JAMA (IF 63.1) Pub Date : 2024-11-13 Wei-Zhen Tang,Tai-Hang Liu,Xia Lan
-
Selective vs Standard Obstetric Thromboprophylaxis Protocol-Reply. JAMA (IF 63.1) Pub Date : 2024-11-13 Macie L Champion,Christina T Blanchard,Akila Subramaniam
-
Selective vs Standard Obstetric Thromboprophylaxis Protocol. JAMA (IF 63.1) Pub Date : 2024-11-13 Wei Xiong
-
Representativeness of Studies Required Under Medicare’s Coverage With Evidence Development Program JAMA (IF 63.1) Pub Date : 2024-11-13 Maryam Mooghali, Sanket S. Dhruva, Joseph S. Ross, Reshma Ramachandran
This study evaluates representation of older adults, women, and people of Black race and Hispanic ethnicity in Centers for Medicare & Medicaid Services national coverage determination (NCD) and coverage with evidence development (CED)–approved studies.
-
Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer JAMA (IF 63.1) Pub Date : 2024-11-13 L. Lee Dupuis, Emily Vettese, Allison C. Grimes, Melissa P. Beauchemin, Lisa M. Klesges, Christina Baggott, Jenna Demedis, Catherine Aftandilian, David R. Freyer, Nicole Crellin-Parsons, Etan Orgel, David Dickens, Kara M. Kelly, Wade Kyono, Alexandra Walsh, Farha Sherani, Daniel Cannone, Andrea D. Orsey, Allison A. King, Lolie Yu, Wendy Woods-Swafford, Scott M. Bradfield, Michael E. Roth, Adam J. Esbenshade
ImportancePediatric patients with cancer commonly experience severely bothersome symptoms. The effectiveness of routine symptom screening with symptom feedback and symptom management care pathways is unknown.ObjectiveTo determine whether thrice-weekly symptom screening with symptom feedback and management care pathways, compared with usual care, improves overall self-reported symptom scores measured
-
Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists JAMA (IF 63.1) Pub Date : 2024-11-13 Sadiya S. Khan, Chiadi E. Ndumele, Dhruv S. Kazi
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.
-
Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial. JAMA (IF 63.1) Pub Date : 2024-11-11 Brett J Manley,C Omar F Kamlin,Susan M Donath,Kate L Francis,Jeanie L Y Cheong,Peter A Dargaville,Jennifer A Dawson,Susan E Jacobs,Pita Birch,Steven M Resnick,Georg M Schmölzer,Brenda Law,Risha Bhatia,Katinka P Bach,Koert de Waal,Javeed N Travadi,Pieter J Koorts,Mary J Berry,Kei Lui,Victor S Rajadurai,Suresh Chandran,Martin Kluckow,Elza Cloete,Margaret M Broom,Michael J Stark,Adrienne Gordon,Vinayak
Importance Bronchopulmonary dysplasia (BPD) is a common adverse outcome in extremely preterm infants born at less than 28 weeks' gestation. Systemic corticosteroids are effective against BPD but may be associated with adverse outcomes. Corticosteroids given directly into the lungs may be effective and safer. Objective To investigate the effectiveness of early intratracheal corticosteroid administration
-
Online Retailer Nonadherence to Age Verification, Shipping, and Flavor Restrictions on E-Cigarettes. JAMA (IF 63.1) Pub Date : 2024-11-11 Raquel M Harati,Shannon E Ellis,Nora Satybaldiyeva,Tomas Mejorado,Gustavo Benitez,Lisa Henriksen,Eric C Leas
-
Intratracheal Budesonide Combined With Surfactant in Extremely Preterm Infants. JAMA (IF 63.1) Pub Date : 2024-11-11 Erik A Jensen
-
Incentivizing Network Adequacy in Medicare Advantage JAMA (IF 63.1) Pub Date : 2024-11-11 John A. Graves, Gabrielle Lyons
This Viewpoint discusses enrollment in Medicare Advantage vs traditional Medicare among older adults and common reasons for plan disenrollment, including the lack of in-network physicians and hospitals.
-
Calcific Aortic Stenosis JAMA (IF 63.1) Pub Date : 2024-11-11 Catherine M. Otto, David E. Newby, Graham S. Hillis
ImportanceCalcific aortic stenosis (AS) restricts the aortic valve opening during systole due to calcification and fibrosis of either a congenital bicuspid or a normal trileaflet aortic valve. In the US, AS affects 1% to 2% of adults older than 65 years and approximately 12% of adults older than 75 years. Worldwide, AS leads to more than 100 000 deaths annually.ObservationsCalcific AS is characterized
-
CDC: 2 in 5 High Schoolers Report Persistent Sadness. JAMA (IF 63.1) Pub Date : 2024-11-08 Samantha Anderer
-
WHO Approves Another HPV Vaccine for Single-Dose Use. JAMA (IF 63.1) Pub Date : 2024-11-08 Samantha Anderer
-
Only About 5% of US Women Now Use Menopausal Hormone Therapy. JAMA (IF 63.1) Pub Date : 2024-11-08 Samantha Anderer
-
WHO Approves 3 Mpox Tests Amid Surging Cases in Africa. JAMA (IF 63.1) Pub Date : 2024-11-08 Samantha Anderer
-
Creatine Likely a Marker, Not a Cause, of Insulin Resistance in Type 2 Diabetes. JAMA (IF 63.1) Pub Date : 2024-11-08 Samantha Anderer
-
Stool Metabolites Could Aid in Endometriosis Diagnosis and Therapy. JAMA (IF 63.1) Pub Date : 2024-11-08 Samantha Anderer
-
New American Heart Association Scientific Statement on Lipoprotein Apheresis. JAMA (IF 63.1) Pub Date : 2024-11-08 Samantha Anderer
-
FDA Authorizes First At-Home COVID-19 and Flu Combo Test. JAMA (IF 63.1) Pub Date : 2024-11-08 Samantha Anderer
-
UN Meeting Highlights Antimicrobial Resistance “Epiphany”—Lack of Antibiotic Access Is a Key Driver JAMA (IF 63.1) Pub Date : 2024-11-08 Kate Schweitzer
This Medical News article discusses the first high-level meeting on antimicrobial resistance at the United Nations since 2016 and a new report on the global burden of bacterial antimicrobial resistance.
-
National Academies President on How to Use Generative AI Responsibly in Scientific Research JAMA (IF 63.1) Pub Date : 2024-11-08 Kirsten Bibbins-Domingo, Yulin Hswen
This Medical News article is an interview with National Academy of Sciences President Marcia McNutt, PhD, and JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, about responsible use of generative AI for scientific research.
-
Industry Payments to Physicians by Competing Manufacturers Within Novel Therapeutic Classes JAMA (IF 63.1) Pub Date : 2024-11-07 Q. Wilton Sun, Joseph S. Ross
This study analyzes the extent and persistence of payments to physicians from competing manufacturers after receipt of payment from manufacturers of first-in-class products entering 6 novel therapeutic classes.
-
Working With Medical Interpreters JAMA (IF 63.1) Pub Date : 2024-11-07 Zara Latif, Jane Kontrimas, Haider J. Warraich
This JAMA Insights discusses the important role that interpreters play in facilitating communication between patients with limited English-language proficiency and their health care team and provides steps that can be taken to improve communication with remote interpreters for patients.
-
Osteophyte JAMA (IF 63.1) Pub Date : 2024-11-07 Lucy Zhao
In this narrative medicine essay, a medical student discusses the challenges of conveying her grandmother’s feelings to her physician while serving as an interpreter for her grandparents’ clinic visits.
-
A Young Woman With Headaches and Peripheral Vision Loss JAMA (IF 63.1) Pub Date : 2024-11-06 Austin D. Peer, M. Aurel Nagy, Marc H. Levin
A 30-year-old nulliparous woman with obesity and history of migraines and depression had 1 month of daily headaches, transient bilateral visual blurring, persistent vision loss in the temporal region of one eye, pulsatile tinnitus, and mild bilateral papilledema. What is the diagnosis and what would you do next?